Navigation Links
Xencor's XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Date:10/1/2013

MONROVIA, Calif., Oct. 1, 2013 /PRNewswire/ -- Xencor, Inc. today announced that the first patient has been dosed in the Phase 2a part of its ongoing Phase 1b/2a clinical trial of XmAb®5871 in patients with active rheumatoid arthritis. XmAb5871 is the first in Xencor's class of therapeutic antibodies targeting the FcγRIIb pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion.

XmAb5871 is an Fc engineered monoclonal antibody that inhibits B cells by dual targeting CD19 and FcγRIIb. Amgen Inc. and Xencor entered into a collaboration and option agreement for XmAb5871 in December 2010. Under that agreement, Amgen has the option to acquire an exclusive worldwide license to XmAb5871, exercisable at any time before completion of a data review period following our planned subsequent Phase 2b proof-of-concept clinical trial. Xencor leads all research, development, and manufacturing activities for XmAb5871 until that time and is eligible for milestone payments.

"XmAb5871 represents a novel therapeutic strategy for engaging the FcγRIIb pathway to suppress autoimmune responses without B-cell depletion," said Bassil Dahiyat, Ph.D., president and CEO of Xencor. "This Phase 2a rheumatoid arthritis data is intended to inform a larger Phase 2 study and may support the potential use of XmAb5871 in other autoimmune diseases, such as lupus."

The Phase 2a portion of the clinical trial will evaluate biweekly doses of XmAb5871 in approximately 30 rheumatoid arthritis patients with active disease on stable non-biologic DMARD therapy. Endpoints include clinical markers of disease response.

XmAb5871 was well tolerated in the Phase 1a dose escalation part of the trial that enrolled 48 healthy male subjects and inhibited multiple biomarkers of immune function.

About Xencor, Inc.

Xencor is developi
'/>"/>

SOURCE Xencor, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sacom SPA, Leader in the Italian Green Biotechnology Fertilizer Industry, Enters the VedoGreen Financial Network
2. U.S. Blood Centers Pursue an Evolving Role in Cell Therapies
3. Blood Centers of America Experiences Record Growth
4. Verenium Enters Agreement To Be Acquired By BASF
5. CCG Investor Relations Announces Company Presenters for NexGen Life Sciences Virtual Conference
6. Independent Living Centers Play A Vital Role In Helping Students Transition Out Of High School
7. Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
8. Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
9. Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.
10. 7 SynCardia Certified Centers Honored Among “Best Children’s Hospitals” for Cardiology and Heart Surgery by U.S. News & World Report
11. VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... 20 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... China, notified,its shareholders today that the Annual ... 2007, has been postponed due the geographical,nature ... the mailing of,proxy materials. The Company is ...
... EDMONTON, Aug. 20 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), announced,today that it is ... bid,which will be conducted pursuant to the rules ... purchase up to 1,000,000 of its Class A ...
... ABUJA, August 20 The Chrome Group today announced ... of its companies on trading,platforms in Europe and the ... Group Chief Communications Officer, Mr. Val Oji said that ... Group was,implementing over the next two years. Chrome recently ...
Cached Biology Technology:Sinovac Announces Postponement of Annual General Meeting 2BioMS Medical announces its intention to renew a normal course issuer bid 2Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4
(Date:4/21/2014)... can help treat and prevent influenza and respiratory ... the lungs and breathing passages, according to research ... new Institute for Biomedical Sciences. , In a ... upcoming publication of the International Journal of Molecular ... ginseng, a well-known herbal medicine, on human health. ...
(Date:4/21/2014)... Like a daily pill to lower cholesterol can reduce ... reduces eye inflammation could help save the vision of ... already targeted with high doses of niacin to decrease ... also be an effective mark for these patients, said ... Georgia at Georgia Regents University. , Martin is ...
(Date:4/21/2014)... domesticated chili pepper now the world,s most ... team of researchers, led by a plant scientist ... from the four-pronged investigation based on linguistic ... traditional archaeological and genetic data suggest a ... the domesticated chili pepper. That region, extending from ...
Breaking Biology News(10 mins):Ginseng can treat and prevent influenza and RSV, researcher finds 2Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3Birthplace of the domesticated chili pepper identified in Mexico 2
... Copenhagen, Herlev Hospital and Rigshospitalet have identified a clear link ... blood. In the long term, the research may well help ... been published in the Journal of the American College ... which the opening of the aortic valve is narrowed ...
... PULLMAN, Wash. A class of drugs used to treat ... treating cancers and immune-related diseases, a new WSU-led study has ... have a major impact on its ability to affect specific ... "This was rather unexpected, given how relatively simple the molecules ...
... iPhone users now have access to a free ... including electricity, natural gas, biodiesel, e85 Ethanol, propane ... Energy Laboratory (NREL) developed the new mobile application ... local stakeholders across the country in an effort ...
Cached Biology News:Danish researchers predict risk of valvular heart disease 2Researcher finds potential new use for old drugs 2NREL developed mobile app for alternative fueling station locations released 2
... Immunogen: Synthetic peptide derived from the C ... protein This peptide sequence is downstream ... Zymed polyclonal Connexin 36 antibody Cat. No. ... 36. Reactivity: Mouse (positive control: mouse ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: